Mark X. Sliwkowski
Genentech · 303 works · 33,865 citations · h-index 64
Top works
- Untangling the ErbB signalling network
- Structure of the Epidermal Growth Factor Receptor Kinase Domain Alone and in Complex with a 4-Anilinoquinazoline Inhibitor
- Identification of Heregulin, a Specific Activator of p185 erbB2
- Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers
- HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.
- Coexpression of erbB2 and erbB3 proteins reconstitutes a high affinity receptor for heregulin.
- Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
- Targeting HER2-Positive Breast Cancer with Trastuzumab-DM1, an Antibody–Cytotoxic Drug Conjugate
- Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin).
- Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
- Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
- The erbB3 gene product is a receptor for heregulin.
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index
- Ligand-Independent HER2/HER3/PI3K Complex Is Disrupted by Trastuzumab and Is Effectively Inhibited by the PI3K Inhibitor GDC-0941
- An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors
- Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer
- Kinetic Analysis of Epidermal Growth Factor Receptor Somatic Mutant Proteins Shows Increased Sensitivity to the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Erlotinib
- Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates
- Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast Cancer
- A Central Role for HER3 in HER2 -Amplified Breast Cancer: Implications for Targeted Therapy